Roche said Wednesday that it has accepted nearly 65 million shares of Poseida Therapeutics (PSTX), or about 66% of the company's stock, and that it intends to complete its acquisition of the biopharmaceutical company.

The shares had been tendered at a price of $9 per share in cash, plus a contingent value right of up to $4 per share. Roche said in November that it agreed to acquire Poseida in a deal worth up to $1.5 billion.

Following completion, Poseida will become a wholly owned subsidiary of Roche, and its shares will cease to be traded on Nasdaq, Roche said.